[1] E. Pardali, S. Dimmeler, A.M. Zeiher, M.A. Rieger: Clonal hematopoiesis, aging, and cardiovascular diseases. Exp Hematol 83:95-104, 2020.
[2] E.J. Benjamin, S.S. Virani, C.W. Callaway, A.M. Chamberlain, A.R. Chang, S. Cheng, et al: Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation 137: e67-e492, 2018.
[3] J.O. Fajemiroye, L.C. da Cunha, R. Saavedra-Rodriguez, K.L. Rodrigues, L.M. Naves, A.A. Mourao, et al: Aging-Induced Biological Changes and Cardiovascular Diseases. Biomed Res Int 2018: 7156435, 2018.
[4] P.K. Shah, Inflammation, infection and atherosclerosis: Trends Cardiovas Med 29: 468-472, 2019.
[5] G. Siasos: The Role of Endothelium in Cardiovascular Diseases. New Insights, Curr Med Chem 27: 1019-1020, 2020.
[6] T.J. Barrett: Macrophages in Atherosclerosis Regression. Arterioscl Throm Vas 40: 20-33, 2020.
[7] H. Xu, J. Jiang, W. Chen, W. Li, Z. Chen: Vascular Macrophages in Atherosclerosis. J Immunol Res 2019: 4354786, 2019.
[8] G.J. Koelwyn, E.M. Corr, E. Erbay, K.J. Moore: Regulation of macrophage immunometabolism in atherosclerosis. Nat Immunol 19: 526-537, 2018.
[9] D.A. Chistiakov, A.A. Melnichenko, V.A. Myasoedova, A.V. Grechko, A.N. Orekhov: Mechanisms of foam cell formation in atherosclerosis. J Mol Med 95: 1153-1165, 2017.
[10] B. Herrero-Fernandez, R. Gomez-Bris, B. Somovilla-Crespo, J.M. Gonzalez-Granado: Immunobiology of Atherosclerosis: A Complex Net of Interactions. Int J Mol Sci 20, 2019.
[11] Krzysztof Sikorski, Anna Czerwoniec, Janusz M, Bujnicki, Joanna Wesoly, Hans A.R, Bluyssen: STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNγ, TLR4 and IL-6 in vascular disease. Cytokine Growth F R 22:211-219,2011.
[12] X.Y. Chen, J. Zhang, J.S. Zhu: The role of m(6)A RNA methylation in human cancer. Mol Cancer 18: 103, 2019.
[13] T. Sun, R. Wu, L. Ming: The role of m6A RNA methylation in cancer. Biomed Pharmacother 112: 108613, 2019.
[14] G. Cao, H.B. Li, Z. Yin, R.A. Flavell: Recent advances in dynamic m6A RNA modification. Open biol 6: 160003, 2016.
[15] J. Chen, C. Wang, W. Fei, X. Fang, X. Hu: Epitranscriptomic m6A modification in the stem cell field and its effects on cell death and survival. Am J Cancer Res 9: 752-764, 2019.
[16] J. Li, L. Zhu, Y. Shi, J. Liu, L. Lin, X. Chen: m6A demethylase FTO promotes hepatocellular carcinoma tumorigenesis via mediating PKM2 demethylation. Am J Transl Res 11: 6084-6092, 2019.
[17] T. Liu, Q. Wei, J. Jin, Q. Luo, Y. Liu, Y. Yang, C. et al: The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic Acids Res 48: 3816-3831, 2020.
[18] Y. Gao, G. Pei, D. Li, R. Li, Y. Shao, Q.C. Zhang, et al: Multivalent m(6)A motifs promote phase separation of YTHDF proteins. Cell Res 29: 767-769, 2019.
[19] A. Quiles-Jimenez, I. Gregersen, M. Mittelstedt Leal de Sousa, A. Abbas, X.Y. Kong, I. Alseth, et al: N6-methyladenosine in RNA of atherosclerotic plaques: An epitranscriptomic signature of human carotid atherosclerosis. Biochem Bioph Res Co, 2020.
[20] D. Jian, Y. Wang, L. Jian, H. Tang, L. Rao, K. Chen, et al: METTL14 aggravates endothelial inflammation and atherosclerosis by increasing FOXO1 N6-methyladeosine modifications. Theranostics 10: 8939-8956, 2020.
[21] J. Huang, X. Dong, Z. Gong, L.Y. Qin, S. Yang, Y.L. Zhu, et al: Solution structure of the RNA recognition domain of METTL3-METTL14 N(6)-methyladenosine methyltransferase. Protein & cell 10: 272-284, 2019.
[22] H. Song, X. Feng, H. Zhang, Y. Luo, J. Huang, M. Lin, et al: METTL3 and ALKBH5 oppositely regulate m(6)A modification of TFEB mRNA, which dictates the fate of hypoxia/reoxygenation-treated cardiomyocytes. Autophagy 15: 1419-1437, 2019.
[23] Y. Kuang, H. Liu, S. Guo, Y. Wang, H. Zhang, Y. Qiao: The antagonist of P2Y11 receptor NF157 ameliorates oxidized LDL-induced vascular endothelial inflammation. Artif Cell Nanomed B 47: 1839-1845, 2019.
[24] J. Cheriyan, A.J. Webb, L. Sarov-Blat, M. Elkhawad, S.M. Wallace, K.M. Maki-Petaja, et al: Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. Circulation 123: 515-523, 2011.
[25] B. Soltani, N. Bodaghabadi, N. Ghaemi, M. Sadeghizadeh: Radiation-induced surge of macrophage foam cell formation, oxidative damage, and cytokine release is attenuated by a nanoformulation of curcumin. Int J Radiat Biol 93: 303-314, 2017.
[26] L. Jiang, X.Q. Chen, M.J. Gao, W. Lee, J. Zhou, Y.F. Zhao, et al: The Pros1/Tyro3 axis protects against periodontitis by modulating STAT/SOCS signalling. J Cell Mol Med 23: 2769-2781, 2019.
[27] H. Dokduang, A. Techasen, N. Namwat, N. Khuntikeo, C. Pairojkul, Y. Murakami, et al: STATs profiling reveals predominantly-activated STAT3 in cholangiocarcinoma genesis and progression. J Hepato-Bil-Pan Sci 21: 767-776, 2014.
[28] Y. Liu, Z. Liu, H. Tang, Y. Shen, Z. Gong, N. Xie, et al: The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 facilitates M1 macrophage polarization through the methylation of STAT1 mRNA, Am J Physiol-Cell Ph 317: C762-C775, 2019.
[29] K. Hirahara, A. Onodera, A.V. Villarino, M. Bonelli, G. Sciume, A. Laurence, et al: Asymmetric Action of STAT Transcription Factors Drives Transcriptional Outputs and Cytokine Specificity. Immunity 42: 877-889, 2015.
[30] X. Cheng, Y. Liu, H. Chu, H.Y. Kao: Promyelocytic leukemia protein (PML) regulates endothelial cell network formation and migration in response to tumor necrosis factor alpha (TNFalpha) and interferon alpha (IFNalpha). J Biol Inorg Chem 287: 23356-23367, 2012.
[31] M. Scarrow, N. Chen, G. Sun: Insights into the N(6)-methyladenosine mechanism and its functionality: progress and questions. Crit Rev Biotechnol 40: 639-652, 2020.
[32] X. Wang, B.S. Zhao, I.A. Roundtree, Z. Lu, D. Han, H. Ma, et al: N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency. Cell 161: 1388-1399, 2015.
[33] J. Chen, Y. Sun, X. Xu, D. Wang, J. He, H. Zhou, et al: YTH domain family 2 orchestrates epithelial-mesenchymal transition/proliferation dichotomy in pancreatic cancer cells. Cell cycle 16: 2259-2271, 2017.
[34] T. Ghazi, S. Nagiah, A.A. Chuturgoon: Fusaric acid decreases p53 expression by altering promoter methylation and m6A RNA methylation in human hepatocellular carcinoma (HepG2) cells. Epigenetics: 1-13, 2020.
[35] Z. Wang, X. Zhang, E. Jiang, H. Yan, H. Zhu, H. Chen, et al: InDels within caprine IGF2BP1 intron 2 and the 3'-untranslated regions are associated with goat growth traits. Anim Genet 51: 117-121, 2020.
[36] X. Liu, P. Wu, R. Su, Y. Xue, C. Yang, D. Wang, et al: IGF2BP2 stabilized FBXL19-AS1 regulates the blood-tumour barrier permeability by negatively regulating ZNF765 by STAU1-mediated mRNA decay. RNA bio:1-12, 2020.
[37] Y.M. Shaalan, H. Handoussa, R.A. Youness, R.A. Assal, A.H. El-Khatib, M.W. Linscheid, et al: Destabilizing the interplay between miR-1275 and IGF2BPs by Tamarix articulata and quercetin in hepatocellular carcinoma. Nat Prod Res 32: 2217-2220, 2018.
[38] S. Kaiser, T.P. Jurkowski, S. Kellner, D. Schneider, A. Jeltsch, M. Helm: The RNA methyltransferase Dnmt2 methylates DNA in the structural context of a tRNA. RNA biology 14: 1241-1251, 2017.